Received Feb 3, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
Patient received 1st dose of GARDASIL9 in August 2014, and 2nd dose in October 2014 (exact dose are unknown.) The 3rd dose was missed. At that time the patient was 17 years old.; No additional AE; This spontaneous report was received from a pharmacist and refers to a 17-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On unspecified date in August 2014, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), Injection (strength, dose, frequency, lot #, and expiration date were not reported). On unspecified date in October 2014, the patient received the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), Injection (strength, dose, frequency, lot #, and expiration date were not reported). The vaccine was administered for prophylaxis. At that time the patient was 17 years old (Inappropriate schedule of vaccine administered). Pharmacist wanted to know if the third dose of GARDASIL 9 needed to be given to a patient or the whole series needed to be repeated. No additional adverse event was reported. Lot # is being requested and will be submitted if received.